908 Devices (MASS)
Market Price (6/21/2026): $8.84 | Market Cap: $325.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
908 Devices (MASS)
Market Price (6/21/2026): $8.84Market Cap: $325.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Trading close to highsDist 52W High is -3.3% Weak multi-year price returns3Y Excs Rtn is -77% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.37 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -41% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 67% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% Key risksMASS key risks include [1] its history of net losses and uncertain profitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Trading close to highsDist 52W High is -3.3% |
| Weak multi-year price returns3Y Excs Rtn is -77% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.37 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -41% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 67% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
| Key risksMASS key risks include [1] its history of net losses and uncertain profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/15/2026
908 Devices (MASS) stock has gained about 30% since 2/28/2026 because of the following key factors:
1. Strong First Quarter Fiscal 2026 Financial Results and Increased Full-Year Revenue Guidance. 908 Devices reported revenue of $13.4 million for fiscal Q1 2026 (ended March 31, 2026), marking a 14% increase year-over-year and surpassing street estimates. Following these results, the company raised its full-year 2026 revenue outlook to a range of $67.0 million to $70.0 million, representing a projected growth of 19% to 25% over fiscal 2025 revenue. This upward revision from the initial guidance of 15% to 20% growth, provided in the Q4 2025 report, signaled robust future performance. Additionally, adjusted gross margins improved to 57% for fiscal Q1 2026, a nearly three percentage point rise over fiscal Q1 2025, and operating cash flow turned positive at $1.2 million for the quarter.
2. Strategic Acquisition Expanding Narcotics Detection Portfolio. On May 6, 2026, 908 Devices announced the acquisition of NIRLAB AG, a move designed to expand its narcotics detection portfolio. This acquisition is expected to broaden the company's reach into the lower-cost, widely-deployable segment of the narcotics detection market and is anticipated to increase recurring revenue opportunities through software subscriptions, thereby strengthening its overall market position. The transaction was valued at $13 million in cash and $2 million in stock.
Show more
908 Devices (MASS) stock has gained about 30% since 2/28/2026 because of the following key factors:
1. Strong First Quarter Fiscal 2026 Financial Results and Increased Full-Year Revenue Guidance. 908 Devices reported revenue of $13.4 million for fiscal Q1 2026 (ended March 31, 2026), marking a 14% increase year-over-year and surpassing street estimates. Following these results, the company raised its full-year 2026 revenue outlook to a range of $67.0 million to $70.0 million, representing a projected growth of 19% to 25% over fiscal 2025 revenue. This upward revision from the initial guidance of 15% to 20% growth, provided in the Q4 2025 report, signaled robust future performance. Additionally, adjusted gross margins improved to 57% for fiscal Q1 2026, a nearly three percentage point rise over fiscal Q1 2025, and operating cash flow turned positive at $1.2 million for the quarter.
2. Strategic Acquisition Expanding Narcotics Detection Portfolio. On May 6, 2026, 908 Devices announced the acquisition of NIRLAB AG, a move designed to expand its narcotics detection portfolio. This acquisition is expected to broaden the company's reach into the lower-cost, widely-deployable segment of the narcotics detection market and is anticipated to increase recurring revenue opportunities through software subscriptions, thereby strengthening its overall market position. The transaction was valued at $13 million in cash and $2 million in stock.
Show more
Updated on 6/15/2026
908 Devices (MASS) stock has gained about 30% since 2/28/2026 because of the following key factors:
1. Strong First Quarter Fiscal 2026 Financial Results and Increased Full-Year Revenue Guidance. 908 Devices reported revenue of $13.4 million for fiscal Q1 2026 (ended March 31, 2026), marking a 14% increase year-over-year and surpassing street estimates. Following these results, the company raised its full-year 2026 revenue outlook to a range of $67.0 million to $70.0 million, representing a projected growth of 19% to 25% over fiscal 2025 revenue. This upward revision from the initial guidance of 15% to 20% growth, provided in the Q4 2025 report, signaled robust future performance. Additionally, adjusted gross margins improved to 57% for fiscal Q1 2026, a nearly three percentage point rise over fiscal Q1 2025, and operating cash flow turned positive at $1.2 million for the quarter.
2. Strategic Acquisition Expanding Narcotics Detection Portfolio. On May 6, 2026, 908 Devices announced the acquisition of NIRLAB AG, a move designed to expand its narcotics detection portfolio. This acquisition is expected to broaden the company's reach into the lower-cost, widely-deployable segment of the narcotics detection market and is anticipated to increase recurring revenue opportunities through software subscriptions, thereby strengthening its overall market position. The transaction was valued at $13 million in cash and $2 million in stock.
3. Positive Analyst Sentiment and Upward Price Target Revisions. Throughout the period, analysts demonstrated increased confidence in 908 Devices, with Zacks upgrading the stock to "Buy" on June 4, 2026, citing rising earnings estimates. The consensus analyst rating for MASS is "Strong Buy" as of June 2026. Analysts have set a median price target of $10.00, with some forecasts reaching as high as $12.00, indicating a significant potential upside.
Show less
908 Devices (MASS) stock has gained about 30% since 2/28/2026 because of the following key factors:
1. Strong First Quarter Fiscal 2026 Financial Results and Increased Full-Year Revenue Guidance. 908 Devices reported revenue of $13.4 million for fiscal Q1 2026 (ended March 31, 2026), marking a 14% increase year-over-year and surpassing street estimates. Following these results, the company raised its full-year 2026 revenue outlook to a range of $67.0 million to $70.0 million, representing a projected growth of 19% to 25% over fiscal 2025 revenue. This upward revision from the initial guidance of 15% to 20% growth, provided in the Q4 2025 report, signaled robust future performance. Additionally, adjusted gross margins improved to 57% for fiscal Q1 2026, a nearly three percentage point rise over fiscal Q1 2025, and operating cash flow turned positive at $1.2 million for the quarter.
2. Strategic Acquisition Expanding Narcotics Detection Portfolio. On May 6, 2026, 908 Devices announced the acquisition of NIRLAB AG, a move designed to expand its narcotics detection portfolio. This acquisition is expected to broaden the company's reach into the lower-cost, widely-deployable segment of the narcotics detection market and is anticipated to increase recurring revenue opportunities through software subscriptions, thereby strengthening its overall market position. The transaction was valued at $13 million in cash and $2 million in stock.
3. Positive Analyst Sentiment and Upward Price Target Revisions. Throughout the period, analysts demonstrated increased confidence in 908 Devices, with Zacks upgrading the stock to "Buy" on June 4, 2026, citing rising earnings estimates. The consensus analyst rating for MASS is "Strong Buy" as of June 2026. Analysts have set a median price target of $10.00, with some forecasts reaching as high as $12.00, indicating a significant potential upside.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 28.3% change in MASS stock from 2/28/2026 to 6/20/2026 was primarily driven by a 20.3% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.90 | 8.85 | 28.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 58 | 8.7% |
| P/S Multiple | 4.7 | 5.6 | 20.3% |
| Shares Outstanding (Mil) | 36 | 37 | -1.9% |
| Cumulative Contribution | 28.3% |
Market Drivers
2/28/2026 to 6/20/2026| Return | Correlation | |
|---|---|---|
| MASS | 28.3% | |
| Market (SPY) | 9.2% | 58.3% |
| Sector (XLV) | -6.4% | 22.3% |
Fundamental Drivers
The 39.4% change in MASS stock from 11/30/2025 to 6/20/2026 was primarily driven by a 30.7% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.35 | 8.85 | 39.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 58 | 8.7% |
| P/S Multiple | 4.3 | 5.6 | 30.7% |
| Shares Outstanding (Mil) | 36 | 37 | -1.9% |
| Cumulative Contribution | 39.4% |
Market Drivers
11/30/2025 to 6/20/2026| Return | Correlation | |
|---|---|---|
| MASS | 39.4% | |
| Market (SPY) | 9.9% | 36.9% |
| Sector (XLV) | -4.4% | 12.4% |
Fundamental Drivers
The 55.8% change in MASS stock from 5/31/2025 to 6/20/2026 was primarily driven by a 46.1% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.68 | 8.85 | 55.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 52 | 58 | 10.9% |
| P/S Multiple | 3.9 | 5.6 | 46.1% |
| Shares Outstanding (Mil) | 35 | 37 | -3.9% |
| Cumulative Contribution | 55.8% |
Market Drivers
5/31/2025 to 6/20/2026| Return | Correlation | |
|---|---|---|
| MASS | 55.8% | |
| Market (SPY) | 28.1% | 31.3% |
| Sector (XLV) | 14.6% | 14.5% |
Fundamental Drivers
The 1.6% change in MASS stock from 5/31/2023 to 6/20/2026 was primarily driven by a 20.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312023 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.71 | 8.85 | 1.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 48 | 58 | 20.3% |
| P/S Multiple | 5.8 | 5.6 | -2.7% |
| Shares Outstanding (Mil) | 32 | 37 | -13.2% |
| Cumulative Contribution | 1.6% |
Market Drivers
5/31/2023 to 6/20/2026| Return | Correlation | |
|---|---|---|
| MASS | 1.6% | |
| Market (SPY) | 85.7% | 21.8% |
| Sector (XLV) | 22.9% | 14.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MASS Return | -55% | -71% | 47% | -80% | 139% | 63% | -85% |
| Peers Return | 39% | -14% | 2% | -4% | 1% | -3% | 15% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| MASS Win Rate | 33% | 33% | 50% | 33% | 50% | 83% | |
| Peers Win Rate | 78% | 43% | 52% | 52% | 47% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MASS Max Drawdown | -69% | -73% | -54% | -83% | -43% | -19% | |
| Peers Max Drawdown | -15% | -32% | -28% | -25% | -34% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, TDY, BRKR, A, DHR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | MASS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.6% | -18.8% |
| % Gain to Breakeven | 34.3% | 23.1% |
| Time to Breakeven | 1 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -11.9% | -7.8% |
| % Gain to Breakeven | 13.5% | 8.5% |
| Time to Breakeven | 246 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.0% | -9.5% |
| % Gain to Breakeven | 44.9% | 10.5% |
| Time to Breakeven | 19 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.3% | -6.7% |
| % Gain to Breakeven | 79.4% | 7.1% |
| Time to Breakeven | 240 days | 31 days |
In The Past
908 Devices's stock fell -25.6% during the 2025 US Tariff Shock. Such a loss loss requires a 34.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MASS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.6% | -18.8% |
| % Gain to Breakeven | 34.3% | 23.1% |
| Time to Breakeven | 1 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.0% | -9.5% |
| % Gain to Breakeven | 44.9% | 10.5% |
| Time to Breakeven | 19 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.3% | -6.7% |
| % Gain to Breakeven | 79.4% | 7.1% |
| Time to Breakeven | 240 days | 31 days |
In The Past
908 Devices's stock fell -25.6% during the 2025 US Tariff Shock. Such a loss loss requires a 34.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About 908 Devices (MASS)
908 Devices Inc. (NASDAQ: MASS) is a commercial-stage technology company that develops and provides purpose-built mass spectrometry (Mass Spec) devices. These innovative devices are designed to analyze and understand unknown and invisible materials across a variety of scientific and industrial applications. The company focuses on bringing sophisticated analytical capabilities to the point-of-need, whether in the field or on the benchtop.
The company's primary product offerings include the MX908, a handheld, battery-powered Mass Spec device engineered for rapid identification of unknown gas, liquid, and solid materials. For laboratory settings, 908 Devices offers Rebel, a compact desktop analyzer that provides real-time insights into the extracellular environment crucial for bioprocesses. Additionally, the ZipChip solution is a plug-and-play, high-resolution separation platform designed to enhance and optimize Mass Spec sample analysis.
908 Devices serves a diverse range of customers and markets globally, including life sciences research, bioprocessing, industrial biotechnology, and forensics. The company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, providing advanced analytical tools to professionals who require quick and accurate material identification and characterization.
AI Analysis | Feedback
Here are 1-3 brief analogies for 908 Devices (MASS):
The Thermo Fisher Scientific of advanced, accessible mass spectrometry.
The FLIR Systems for identifying unknown chemical and biological materials using mass spectrometry.
AI Analysis | Feedback
- MX908: A handheld, battery-powered Mass Spec device for rapid analysis of unknown gas, liquid, and solid materials.
- Rebel: A small desktop analyzer providing real-time information on the extracellular environment in bioprocesses.
- ZipChip solution: A plug-and-play, high-resolution separation platform designed to optimize Mass Spec sample analysis.
AI Analysis | Feedback
908 Devices Inc. sells its specialized mass spectrometry devices primarily to other organizations and companies, rather than individuals. Based on the description, the company's major customers can be categorized into the following types of organizations, as specific company names are not provided in the background information:
- Life Sciences Research & Biopharma Companies: This category includes pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations (CROs). These customers utilize 908 Devices' technology for drug discovery, development, and various research applications, particularly the ZipChip solution and Rebel analyzer for optimizing sample analysis and real-time bioprocess information.
- Bioprocessing & Industrial Biotech Organizations: Customers in this segment are involved in the manufacturing of biologics, cell and gene therapies, and other industrial applications of biotechnology. They rely on devices like the Rebel for monitoring and optimizing bioprocesses.
- Forensic & Public Safety Agencies: This category encompasses government entities such as law enforcement agencies, homeland security, military units, and hazardous materials (hazmat) teams. They use devices like the MX908 for rapid, on-site analysis of unknown substances for security, safety, and investigative purposes.
AI Analysis | Feedback
null
AI Analysis | Feedback
Kevin J. Knopp, PhD
CEO & Co-founder
Kevin J. Knopp is the co-founder of 908 Devices, established in 2012, and has served as its CEO since February 2012, holding a tenure of over 14 years. His total yearly compensation was approximately $1.99 million as of September 30, 2025.
Joseph H. Griffith
Chief Financial Officer and Treasurer
Joseph H. Griffith serves as the Chief Financial Officer and Treasurer of 908 Devices. His total yearly compensation was approximately $1.24 million as of September 30, 2025.
Jon Frattaroli
VP, Strategy
Jon Frattaroli is the Vice President of Strategy at 908 Devices.
John Kenneweg
VP, Government
John Kenneweg holds the position of Vice President of Government at 908 Devices.
Kevin McCallion, PhD
VP, Products & Production
Kevin McCallion is the Vice President of Products & Production at 908 Devices. He joined the company in 2013, initially as the Director of Component Engineering. Prior to 908 Devices, he was the Vice President of Engineering for TeraDiode and the Director of Engineering at Finisar Corp. He also co-founded Azna LLC, where he served as the Vice President of Product Development. Dr. McCallion is an inventor on over 30 U.S. patents.
AI Analysis | Feedback
Here are the key risks to 908 Devices (MASS):
- History of Net Losses and Challenges to Achieve Profitability: 908 Devices has a history of net losses and faces significant challenges in achieving and maintaining profitability, as indicated by its negative operating and net margins. The company's financial health grades, including a low Piotroski F-Score and an Altman Z-Score in the distress zone, suggest poor business operations and a possibility of bankruptcy within the next two years. Additionally, the company has experienced negative free cash flow, highlighting ongoing cash flow challenges.
- Intense Competition and Need for Continuous Innovation: The company operates in the highly competitive medical devices and instruments industry. To remain competitive, 908 Devices must continuously innovate and adapt to rapid technological changes. A failure to develop new products or enhance existing ones could negatively impact market acceptance and its competitive position.
- Dependence on Limited Suppliers and Supply Chain Disruptions: 908 Devices relies on a limited number of suppliers for key components for its devices. This dependence poses risks of supply chain disruptions, which could adversely affect its operations, lead to reduced sales, and impact cash flows.
AI Analysis | Feedback
null
AI Analysis | Feedback
For 908 Devices (symbol: MASS), the addressable market for its main products has evolved following a strategic divestiture in March 2025.
- MX908 (Handheld Devices): The total addressable market (TAM) for handheld devices, including the MX908, was estimated to be $1.5 billion globally at the time of 908 Devices' IPO in 2020. This market is projected to expand to $2.5 billion globally by 2027. This growth is driven by increasing worldwide concerns regarding illicit drugs, toxic industrial materials, and security threats, alongside software application extensions into GxP facilities for raw material inspection, counterfeit and adulteration detection, contamination and cleaning validation, and other quality assurance and quality control assays.
- Rebel and ZipChip Solution: These products, which were part of 908 Devices' bioprocessing desktop portfolio, were divested to Repligen Corporation in March 2025. Therefore, the addressable markets for Rebel and ZipChip Solution are null for 908 Devices Inc.
AI Analysis | Feedback
908 Devices Inc. (MASS) is positioned for future revenue growth over the next 2-3 years, driven by several key factors:
- Accelerated Demand in Health, Safety, and Defense Technology Markets: The company is strategically focused on addressing critical issues such as the illicit drug crisis, toxic industrial materials, and global security threats. This focus is supported by increased U.S. funding to combat the illicit drug crisis and growing NATO defense budgets, driving demand for its handheld chemical detection tools.
- Growth from Recently Launched Products and Next-Generation Innovation: Strong demand for newly introduced products like VipIR and XplorIR is contributing significantly to revenue. Additionally, the anticipated commercial launch of a next-generation MX908 mass spectrometry platform in late 2026 is expected to open new customer opportunities and drive growth in 2027 and beyond.
- Contributions from the Department of Defense's AVCAD Program: The company's partnership with Smiths Detection on the Department of Defense's AVCAD program is nearing its next phase, with an initial production run expected in the second half of 2026. This program is projected to contribute $2 million-$3 million in 2026, with potential for over $10 million annually.
- Expansion of Recurring Revenue Streams: 908 Devices is actively increasing its recurring revenue, which includes consumables, accessories, software, and service revenue. This strategy, supported by new programs like the TeamLeader software platform, aims to grow recurring revenue to over 40% of total revenues from 35% in 2025, providing greater revenue visibility and predictability.
- Broadening Customer Base and International Expansion: The company is expanding its installed base of devices, which grew 24% year-over-year to 3,736 devices by the end of 2025. Growth in the U.S. state and local sales channel (up 38% in 2025) and increased international sales, particularly to NATO-aligned countries, are also key drivers.
AI Analysis | Feedback
Share Issuance
- The company's common stock began trading on The Nasdaq Global Market on December 18, 2020.
- The number of shares outstanding increased from 27,297,871 as of March 26, 2021, to 36,101,051 at the end of 2025.
- As of March 11, 2026, the number of shares outstanding reached 37.38 million, representing a 5.35% increase in one year.
Outbound Investments
- In August 2022, 908 Devices acquired Trace Analytics GmbH (later renamed 908 Devices GmbH), gaining microfluidic aseptic sampling technology for bioprocess applications.
- The company acquired RedWave in April 2024, which expanded its product portfolio with FTIR technology.
Capital Expenditures
- Capital expenditures were $4 million in 2022 and $4 million in 2023.
- Capital expenditure was USD -955.0 thousand in 2025, marking a 58.6% decrease year-over-year.
- In the last 12 months (prior to March 07, 2026), capital expenditures were $602K, primarily impacting free cash flow.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| 908 Devices Earnings Notes | 12/16/2025 | |
| How Low Can 908 Devices Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 152.12 |
| Mkt Cap | 32.3 |
| Rev LTM | 6,729 |
| Op Inc LTM | 1,370 |
| FCF LTM | 1,070 |
| FCF 3Y Avg | 1,124 |
| CFO LTM | 1,317 |
| CFO 3Y Avg | 1,364 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.6% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 6.9% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 7.2% |
| Op Inc Chg 3Y Avg | 1.2% |
| Op Mgn LTM | 18.6% |
| Op Mgn 3Y Avg | 18.3% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 18.7% |
| CFO/Rev 3Y Avg | 18.9% |
| FCF/Rev LTM | 15.0% |
| FCF/Rev 3Y Avg | 16.4% |
Price Behavior
Price Behavior
| Market Price | $8.85 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 12/18/2020 | |
| Distance from 52W High | -3.3% | |
| 50 Days | 200 Days | |
| DMA Price | $7.62 | $6.89 |
| DMA Trend | up | up |
| Distance from DMA | 16.1% | 28.5% |
| 3M | 1YR | |
| Volatility | 64.2% | 63.8% |
| Downside Capture | 237.96 | 227.46 |
| Upside Capture | 251.73 | 187.37 |
| Correlation (SPY) | 54.5% | 32.1% |
MASS Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 5.23 | 2.56 | 2.38 | 1.60 | 1.55 | 1.41 |
| Up Beta | 10.00 | 2.13 | 2.20 | 2.34 | 1.34 | 1.63 |
| Down Beta | 2.69 | 2.51 | 2.61 | -0.34 | 0.54 | 0.37 |
| Up Capture | 465% | 286% | 274% | 264% | 303% | 549% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 11 | 22 | 33 | 60 | 124 | 338 |
| Down Capture | 399% | 341% | 219% | 164% | 159% | 113% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 9 | 17 | 26 | 60 | 120 | 392 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MASS | |
|---|---|---|---|---|
| MASS | 24.2% | 64.7% | 0.59 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 14.4% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 31.7% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 19.0% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -5.3% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 11.7% |
| Bitcoin (BTCUSD) | -40.0% | 42.5% | -1.08 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MASS | |
|---|---|---|---|---|
| MASS | -25.9% | 94.9% | 0.08 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 21.1% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 30.8% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 9.9% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | 5.5% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 28.4% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | 16.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MASS | |
|---|---|---|---|---|
| MASS | -15.5% | 94.2% | 0.07 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 20.7% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 31.0% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 10.3% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 6.7% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 28.0% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | 17.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 13.7% | 7.9% | 24.4% |
| 3/3/2026 | -4.4% | -3.7% | -7.4% |
| 11/10/2025 | -13.3% | -25.7% | -10.8% |
| 8/5/2025 | -2.8% | -1.4% | -15.3% |
| 5/13/2025 | -18.8% | -16.8% | 27.1% |
| 3/4/2025 | 96.0% | 52.5% | 105.6% |
| 11/12/2024 | -19.3% | -34.8% | -37.6% |
| 8/6/2024 | 0.0% | -8.2% | -19.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 7 | 10 |
| # Negative | 11 | 15 | 12 |
| Median Positive | 11.0% | 7.9% | 24.6% |
| Median Negative | -12.4% | -9.0% | -13.1% |
| Max Positive | 96.0% | 52.5% | 105.6% |
| Max Negative | -22.0% | -38.2% | -44.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 13.7% | 7.9% | 24.4% |
| 3/3/2026 | -4.4% | -3.7% | -7.4% |
| 11/10/2025 | -13.3% | -25.7% | -10.8% |
| 8/5/2025 | -2.8% | -1.4% | -15.3% |
| 5/13/2025 | -18.8% | -16.8% | 27.1% |
| 3/4/2025 | 96.0% | 52.5% | 105.6% |
| 11/12/2024 | -19.3% | -34.8% | -37.6% |
| 8/6/2024 | 0.0% | -8.2% | -19.4% |
| 4/30/2024 | -1.0% | -2.3% | 9.6% |
| 3/5/2024 | -3.7% | -7.9% | -8.6% |
| 11/7/2023 | 4.1% | -4.4% | 24.9% |
| 8/8/2023 | 22.0% | 13.1% | 6.1% |
| 5/9/2023 | 6.2% | 2.5% | 31.7% |
| 3/7/2023 | 2.9% | -12.3% | -6.9% |
| 11/14/2022 | -22.0% | -38.2% | -44.2% |
| 8/9/2022 | -12.4% | -9.0% | -9.7% |
| 5/10/2022 | 14.4% | 3.4% | 2.3% |
| 3/7/2022 | 15.1% | 10.1% | 27.9% |
| 1/10/2022 | -4.4% | -11.8% | -22.4% |
| 11/4/2021 | 11.0% | -2.3% | -30.0% |
| 8/4/2021 | 8.0% | 1.1% | 16.5% |
| 5/13/2021 | -16.5% | -16.3% | -7.3% |
| SUMMARY STATS | |||
| # Positive | 11 | 7 | 10 |
| # Negative | 11 | 15 | 12 |
| Median Positive | 11.0% | 7.9% | 24.6% |
| Median Negative | -12.4% | -9.0% | -13.1% |
| Max Positive | 96.0% | 52.5% | 105.6% |
| Max Negative | -22.0% | -38.2% | -44.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/15/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/15/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/11/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 12/18/2020 | 424B4 |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 67.00 Mil | 68.50 Mil | 70.00 Mil | 3.8% | Raised | Guidance: 66.00 Mil for 2026 | |
| 2026 Revenue Growth | 19.0% | 22.0% | 25.0% | 25.7% | 4.5% | Raised | Guidance: 17.5% for 2026 |
Prior: Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 64.50 Mil | 66.00 Mil | 67.50 Mil | 20.0% | Higher New | Guidance: 55.00 Mil for 2025 | |
| 2026 Revenue Growth | 15.0% | 17.5% | 20.0% | 16.7% | 2.5% | Higher New | Guidance: 15.0% for 2025 |
Insider Activity
Updated 6/12/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Awm, Investment Company, Inc | Limited Partnership | Sell | 6042026 | 8.97 | 39,782 | 356,856 | 43,842,261 | Form | |
| 2 | Brown, Christopher D | Direct | Sell | 6042026 | 8.73 | 20,000 | 174,600 | 7,643,630 | Form | |
| 3 | Awm, Investment Company, Inc | Limited Partnership | Sell | 6042026 | 8.95 | 2,500 | 22,375 | 44,099,093 | Form | |
| 4 | Brown, Christopher D | Direct | Sell | 5292026 | 9.00 | 30,000 | 270,000 | 8,060,031 | Form | |
| 5 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5292026 | 8.66 | 170,442 | 1,475,925 | 42,688,876 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Awm, Investment Company, Inc | Limited Partnership | Sell | 6042026 | 8.97 | 39,782 | 356,856 | 43,842,261 | Form | |
| 2 | Brown, Christopher D | Direct | Sell | 6042026 | 8.73 | 20,000 | 174,600 | 7,643,630 | Form | |
| 3 | Awm, Investment Company, Inc | Limited Partnership | Sell | 6042026 | 8.95 | 2,500 | 22,375 | 44,099,093 | Form | |
| 4 | Brown, Christopher D | Direct | Sell | 5292026 | 9.00 | 30,000 | 270,000 | 8,060,031 | Form | |
| 5 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5292026 | 8.66 | 170,442 | 1,475,925 | 42,688,876 | Form | |
| 6 | Griffith, Joseph H IV | Chief Financial Officer | Direct | Sell | 5292026 | 9.03 | 6,940 | 62,668 | 1,200,593 | Form |
| 7 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5292026 | 8.25 | 16,500 | 136,166 | 42,089,292 | Form | |
| 8 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5132026 | 8.25 | 5,000 | 41,257 | 42,220,062 | Form | |
| 9 | Kenneweg, John | SVP, Sales & Product Marketing | Direct | Sell | 5112026 | 8.11 | 18,255 | 148,048 | 468,628 | Form |
| 10 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5082026 | 8.20 | 3,025 | 24,805 | 41,998,063 | Form | |
| 11 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5082026 | 8.20 | 12,819 | 105,170 | 42,044,392 | Form | |
| 12 | Awm, Investment Company, Inc | Limited Partnership | Sell | 5082026 | 8.05 | 62,365 | 502,155 | 41,366,999 | Form | |
| 13 | Brown, Christopher D | Direct | Sell | 5072026 | 7.23 | 20,000 | 144,600 | 6,691,792 | Form | |
| 14 | Kenneweg, John | SVP, Sales & Product Marketing | Direct | Sell | 5042026 | 6.83 | 7,787 | 53,185 | 519,346 | Form |
| 15 | McCallion, Kevin J | SVP, Products and Production | Direct | Sell | 4142026 | 7.01 | 2,693 | 18,878 | 314,924 | Form |
| 16 | Brown, Christopher D | Direct | Sell | 4102026 | 7.07 | 17,578 | 124,276 | 6,685,102 | Form | |
| 17 | McCallion, Kevin J | SVP, Products and Production | Direct | Sell | 4102026 | 7.03 | 5,420 | 38,103 | 315,823 | Form |
| 18 | Brown, Christopher D | Direct | Sell | 4102026 | 7.04 | 7,392 | 52,040 | 6,780,484 | Form | |
| 19 | McCallion, Kevin J | SVP, Products and Production | Direct | Sell | 4102026 | 7.05 | 18,580 | 130,989 | 316,721 | Form |
| 20 | Brown, Christopher D | Direct | Sell | 4102026 | 7.05 | 15,030 | 105,962 | 6,842,229 | Form | |
| 21 | McCallion, Kevin J | SVP, Products and Production | Direct | Sell | 3042026 | 7.00 | 7 | 49 | 314,426 | Form |
| 22 | Knopp, Kevin J | President and CEO | Direct | Sell | 2032026 | 6.18 | 34,764 | 214,842 | 4,919,082 | Form |
| 23 | Griffith, Joseph H IV | Chief Financial Officer | Direct | Sell | 2032026 | 6.18 | 23,175 | 143,222 | 864,557 | Form |
| 24 | Griffith, Joseph H IV | Chief Financial Officer | Direct | Sell | 10062025 | 9.05 | 4,292 | 38,849 | 841,156 | Form |
| 25 | Griffith, Joseph H IV | Chief Financial Officer | Direct | Sell | 10062025 | 9.04 | 708 | 6,398 | 878,537 | Form |
| 26 | Griffith, Joseph H IV | Chief Financial Officer | Direct | Sell | 9232025 | 7.07 | 5,000 | 35,338 | 692,140 | Form |
| 27 | Turner, Michael S | Chief Legal & Admin Officer | Direct | Sell | 6182025 | 7.50 | 1,373 | Form | ||
| 28 | Turner, Michael S | Chief Legal & Admin Officer | Direct | Sell | 6182025 | 7.51 | 7,148 | 53,653 | 10,306 | Form |
| 29 | Turner, Michael S | Chief Legal & Admin Officer | Direct | Sell | 6182025 | 7.51 | 16,082 | 120,839 | 64,026 | Form |
| 30 | Griffith, Joseph H IV | Chief Financial Officer | Direct | Sell | 6062025 | 7.08 | 6,940 | 49,135 | 728,744 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/20/2026